{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:58:33Z","timestamp":1780876713701,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48035-y","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:34:30Z","timestamp":1776260070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CEP72 promotes malignant progression and shapes the tumor immune microenvironment in hepatocellular carcinoma: integrated multi-cohort bioinformatics and in vitro validation"],"prefix":"10.1038","volume":"16","author":[{"given":"Mingyan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"48035_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745 (2020).","journal-title":"N. Engl. J. Med."},{"key":"48035_CR2","doi-asserted-by":"publisher","unstructured":"Roy, A. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Clin. Exp. Hepatol. 12, 1575\u20131576. https:\/\/doi.org\/10.1016\/j.jceh.2022.07.003 (2022).","DOI":"10.1016\/j.jceh.2022.07.003"},{"key":"48035_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten, T. F. et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 20, 780\u2013798. https:\/\/doi.org\/10.1038\/s41571-023-00816-4 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"48035_CR4","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","author":"J Li","year":"2025","unstructured":"Li, J. et al. Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma: A narrative review. Liver Cancer https:\/\/doi.org\/10.1159\/000549355 (2025).","journal-title":"Liver Cancer"},{"key":"48035_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen, K. Y., Zhu, Y., Xie, S. Z. & Qin, L. X. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: Current status and prospectives. J. Hematol. Oncol. 17, 25. https:\/\/doi.org\/10.1186\/s13045-024-01549-2 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"48035_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li, J. et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: Implications for postoperative recurrence risk. Front. Immunol. 17, 1714314. https:\/\/doi.org\/10.3389\/fimmu.2026.1714314 (2026).","journal-title":"Front. Immunol."},{"key":"48035_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/cm.22030","volume":"82","author":"S Tyagi","year":"2025","unstructured":"Tyagi, S., Arora, A., Ranganath, P. & Dalal, A. CEP72 emerges as a key centriolar satellite protein in health and disease. Cytoskeleton (Hoboken) 82, 737\u2013746. https:\/\/doi.org\/10.1002\/cm.22030 (2025).","journal-title":"Cytoskeleton (Hoboken)"},{"key":"48035_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/1759-7714.12617","volume":"9","author":"YC Zhu","year":"2018","unstructured":"Zhu, Y. C. et al. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing. Thorac. Cancer 9, 652\u2013655. https:\/\/doi.org\/10.1111\/1759-7714.12617 (2018).","journal-title":"Thorac. Cancer"},{"key":"48035_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"48035_CR10","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2026.5729","author":"XM Chen","year":"2026","unstructured":"Chen, X. M. et al. ZG16B: A key regulator of tumor progression and immune microenvironment modulation in cancer (Review). Int. J. Mol. Med. https:\/\/doi.org\/10.3892\/ijmm.2026.5729 (2026).","journal-title":"Int. J. Mol. Med."},{"key":"48035_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065 (2016).","journal-title":"Cell"},{"key":"48035_CR12","doi-asserted-by":"publisher","unstructured":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 169, 1327\u20131341.e1323. https:\/\/doi.org\/10.1016\/j.cell.2017.05.046 (2017).","DOI":"10.1016\/j.cell.2017.05.046"},{"key":"48035_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrg2825","volume":"11","author":"JT Leek","year":"2010","unstructured":"Leek, J. T. et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 11, 733\u2013739. https:\/\/doi.org\/10.1038\/nrg2825 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"48035_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn0086","volume":"10","author":"S Chodisetty","year":"2024","unstructured":"Chodisetty, S., Arora, A., Malik, K. K., Goel, H. & Tyagi, S. M. MLL\/WDR5 complex recruits centriolar satellite protein Cep72 to regulate microtubule nucleation and spindle formation. Sci. Adv. 10, eadn0086. https:\/\/doi.org\/10.1126\/sciadv.adn0086 (2024).","journal-title":"Sci. Adv."},{"key":"48035_CR15","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673344143250604061421","author":"W Zhang","year":"2025","unstructured":"Zhang, W., Liu, C. & Zhou, X. NPLOC4 constructs tumor immunosuppressive microenvironment in pan-cancer and hepatocellular carcinoma. Curr. Med. Chem. https:\/\/doi.org\/10.2174\/0109298673344143250604061421 (2025).","journal-title":"Curr. Med. Chem."},{"key":"48035_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02540-0","volume":"16","author":"N Tan","year":"2025","unstructured":"Tan, N. & Wei, Q. Elevated CEP72 expression facilitates the progression of hepatocellular carcinoma and is associated with unfavorable outcomes. Discov. Oncol. 16, 937. https:\/\/doi.org\/10.1007\/s12672-025-02540-0 (2025).","journal-title":"Discov. Oncol."},{"key":"48035_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s13402-019-00487-3","volume":"43","author":"C Ye","year":"2020","unstructured":"Ye, C. et al. Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4. Cell Oncol. (Dordr.) 43, 279\u2013295. https:\/\/doi.org\/10.1007\/s13402-019-00487-3 (2020).","journal-title":"Cell Oncol. (Dordr.)"},{"key":"48035_CR18","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1002\/jcp.29333","volume":"235","author":"F Rahmani","year":"2020","unstructured":"Rahmani, F. et al. Role of regulatory miRNAs of the PI3K\/AKT\/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J. Cell. Physiol. 235, 4146\u20134152. https:\/\/doi.org\/10.1002\/jcp.29333 (2020).","journal-title":"J. Cell. Physiol."},{"key":"48035_CR19","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1016\/j.molcel.2024.10.010","volume":"84","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Spatial organization of PI3K-PI(3,4,5)P\u2009<\u2009sub>3-AKT signaling by focal adhesions. Mol. Cell. 84, 4401\u20134418e4409. https:\/\/doi.org\/10.1016\/j.molcel.2024.10.010 (2024).","journal-title":"Mol. Cell"},{"key":"48035_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/tox.23965","volume":"39","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Family with sequence similarity 111 member B contributes to tumor growth and metastasis by mediating cell proliferation, invasion, and EMT via transforming acidic coiled-coil protein 3\/PI3K\/AKT signaling pathway in hepatocellular carcinoma. Environ. Toxicol. 39, 409\u2013420. https:\/\/doi.org\/10.1002\/tox.23965 (2024).","journal-title":"Environ. Toxicol."},{"key":"48035_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: From molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"48035_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101438","volume":"5","author":"NK Altorki","year":"2024","unstructured":"Altorki, N. K. et al. A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer. Cell Rep. Med. 5, 101438. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101438 (2024).","journal-title":"Cell Rep. Med."},{"key":"48035_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080882","author":"TC Huang","year":"2021","unstructured":"Huang, T. C. et al. Predicting agents that can overcome 5-FU resistance in colorectal cancers via pharmacogenomic analysis. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines9080882 (2021).","journal-title":"Biomedicines"},{"key":"48035_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754. https:\/\/doi.org\/10.1016\/j.cell.2016.06.017 (2016).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48035-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:23:16Z","timestamp":1780874596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48035-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48035"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48035-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9026891\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available de-identified datasets. All in vitro experiments were performed in established cell lines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17604"}}